Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: SUSTIVA

Summary for Tradename: SUSTIVA

Suppliers: see list2
patent expirations by year for

Clinical Trials for: SUSTIVA

Sustiva Levels With Use of a Gel Capsule
Status: Completed Condition: HIV; HIV Infections

Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2
Status: Completed Condition: Pharmacokinetics; Drug Interactions; Pharmacodynamics; Intestinal Transporter Expression

Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients
Status: Completed Condition: HIV

Efavirenz Comparative Bioavailability
Status: Completed Condition: Healthy

Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers
Status: Active, not recruiting Condition: Healthy Volunteers

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
Status: Active, not recruiting Condition: Hyperlipidemia; HIV

Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
Status: Completed Condition: HIV Infections

Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
Status: Completed Condition: Healthy

PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen
Status: Completed Condition: HIV Infection

Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz
Status: Recruiting Condition: Sleep Disorders; HIV Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
CAPSULE;ORAL020972Sep 17, 1998DISCNNo5,519,021*PED<disabled><disabled>
Bristol Myers Squibb
CAPSULE;ORAL020972Sep 17, 1998DISCNNo5,663,169*PED<disabled>Y<disabled>
Bristol Myers Squibb
CAPSULE;ORAL020972Sep 17, 1998DISCNNo6,238,695*PED<disabled>Y<disabled>
Bristol Myers Squibb
CAPSULE;ORAL020972Sep 17, 1998DISCNNo6,555,133*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SUSTIVA

Drugname Dosage Strength RLD Submissiondate
efavirenzTablets600 mgSustiva4/9/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology